Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists have individually improved outcomes in heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF). However, the efficacy and safety of combining these agents remain untested in randomized trials, necessitating dedicated studies to evaluate potential synergistic benefits.
Hypertension, a prevalent lifestyle disorder, targets a blood pressure (BP) of less than 140/90 mmHg, with amlodipine, a calcium channel blocker, serving as a first-line treatment. Understanding its usage patterns, effectiveness, and tolerability, particularly in diverse populations with comorbidities, is critical for optimizing therapeutic strategies.
This comprehensive systematic review and meta-analysis, published in The Lancet Public Health, evaluates the relationship between daily step count and a wide range of adult health outcomes. Unlike previous reviews that mostly focused on all-cause mortality and cardiovascular disease, this study incorporates data from 57 studies across 35 cohorts to examine broader health outcomes such as cancer, type 2 diabetes, dementia, depressive symptoms, physical function, and falls. Data from 24 cohorts were used in meta-analyses.
This study, using data from the EuroTR registry, investigated the impact of prior heart failure hospitalizations (HFHs) on outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair (T-TEER) for symptomatic tricuspid regurgitation (TR). Among 1000 patients analyzed, 63.9% experienced at least one HFH in the year before T-TEER. These patients presented with more advanced heart failure symptoms, worse renal function, and higher natriuretic peptide levels. Despite similar procedural success across all groups—defined as achieving residual TR grade ≤2—the presence of prior HFHs was linked to significantly higher risks of all-cause mortality and combined mortality/HFH outcomes.
This study, published in the European Journal of Heart Failure, explores the clinical characteristics, management, and outcomes of patients with heart failure (HF) who also have a history of cancer. Drawing from the ESC-HFA EORP Heart Failure Long-Term Registry, the research evaluated 9,017 patients, 904 (10%) of whom had a past cancer diagnosis. The most common cancers reported were breast, prostate, and gastrointestinal.
